Innovus Pharmaceuticals (OTC:INNV) announced today that it has inked an agreement with its current partner, Acon Laboratories, to sell Acon’s FDA-cleared glucose monitor, test strips and lancet device. The San Diego, Calif.-based company plans to sell Acon’s glucose testing kit with its GlucoGorx glucose supplement. Get the full story at our sister site, Drug Delivery Business News.
Drug-Device Combinations
Shares in Titan Pharmaceuticals fall after Q3 miss
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell today after the company missed expectations on Wall Street with its third quarter results. The San Francisco, Calif.-based company posted a net loss of -$4.2 million on sales of $40,000 for the 3 months ended Sept. 30, for bottom-line loss of -60% on sales growth of 53.8% compared with the same […]
OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017
OncoSec Medical (NSDQ:ONCS) announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]
Aerie Pharmaceuticals misses EPS estimates by 7 cents in Q3
Shares in Aerie Pharmaceuticals (NSDQ:AERI) fell slightly today after the company missed earnings expectations on Wall Street with its third quarter results. The Irvine, Calif.-based company posted a net loss of -$32.4 million, or -89¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -36% compared with the same period last year. Get […]
QuiO, SHL Group partner for connected drug-delivery tech
SHL Group and the New York-based startup QuiO announced today that the two companies have inked a strategic partnership to combine SHL’s drug-delivery systems and QuiO’s ConnectedRx solution. As part of their collaboration, the companies hope to integrate connectivity into drug-delivery devices in an effort to boost user experience and improve adherence. Get the full story at our […]
Clearside Biomedical misses Q3 earnings estimates
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the company missed expectations on Wall Street with its third quarter results. The Alpharetta, Ga.-based company posted a net loss of -$18.3 million for the 3 months ended Sept. 30, for bottom-line loss of -226% compared with the same period last year. Get the full story at our […]
Startup aims to disrupt asthma, COPD space with digital inhaler
Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or chronic obstructive pulmonary disease in the U.S. They’re stepping into a highly competitive market, […]
Bellerophon Therapeutics misses EPS estimates in Q3
Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed EPS expectations on Wall Street with its third quarter results. The Warren, N.J.-based company posted a net loss of -$7.6 million for the 3 months ended Sept. 30, for bottom-line loss of -81% compared with the same period last year. Get the full story at […]
Surmodics Q4 results top sales, earnings estimates
Shares in Surmodics (NSDQ:SRDX) fell today even though the medical device maker beat expectations on Wall Street with its fourth quarter results. The Eden Prairie, Minn.-based company posted profits of $400,000 on sales of $20.1 million for the 3 months ended Sept. 30, for bottom-line loss of -84.9% on sales growth of 10.4% compared with the same […]
Ocular shares fall on mixed Q3 results
Shares in Ocular Therapeutix (NSDQ:OCUL) fell yesterday after the company beat sales expectations but missed earnings estimates on Wall Street with its third quarter results. The Bedford, Mass.-based company posted a net loss of -$15.6 million on sales of $520,ooo for the 3 months ended Sept. 30, for bottom-line loss of -62% on sales growth of 8.3% […]
Insulet up-sizes and prices $350m private placement
Insulet (NSDQ:PODD) up-sized the private placement that it announced yesterday, citing strong investor demand. The Billerica, Mass.-based company said today it plans to offer $350 million in convertible senior notes due in 2024, up from $300 million. Get the full story at our sister site, Drug Delivery Business News.